Inventor · disambiguated record
Samarth Kulkarni
Also filed as: KULKARNI SAMARTH
10 granted patents·14 pending applications·58 citations·filing 2005–2024
84Inventor score
Top patents by PatentIndex Score
24 records- 0194US11559588B2Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Granted Jan 24, 2023·12 cites·18 claims
- 0294US7625764B2Stimuli-responsive polymer devicesUNIV WASHINGTON·Filed 2005·Granted Dec 1, 2009·41 cites·12 claims
- 0386US11459587B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2017·Granted Oct 4, 2022·3 cites·17 claims
- 0479US12442020B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2022·Granted Oct 14, 2025·0 cites·18 claims
- 0579US11427838B2Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disordersVERTEX PHARMA·Filed 2017·Granted Aug 30, 2022·1 cites·6 claims
- 0676US11174469B2Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disordersCRISPR THERAPEUTICS AG·Filed 2017·Granted Nov 16, 2021·1 cites·11 claims
- 0775US2024318200A1Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0875US2024066150A1Materials and methods for treatment of pain related disordersVERTEX PHAMACEUTICALS INCORPORATED·Filed 2023·Application pending·0 cites
- 0970US2023227855A1Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related DisordersVERTEX PHARMA·Filed 2022·Application pending·0 cites
- 1070US2023330270A1Materials and methods for treatment of friedreich ataxia and other related disordersCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1169US2022364082A1Compositions and methods for editing the angiopoietin-like 4 (angptl4) geneCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1267US2022340897A1Materials and methods for treatment of apolipoprotein c3 (apociii)-related disordersCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1360US11920148B2Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2018·Granted Mar 5, 2024·0 cites·18 claims
- 1459US11801313B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2017·Granted Oct 31, 2023·0 cites·10 claims
- 1559US11564997B2Materials and methods for treatment of friedreich ataxia and other related disordersCRISPR THERAPEUTICS AG·Filed 2017·Granted Jan 31, 2023·0 cites·14 claims
- 1655US2019185849A1Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 1752US2020123570A1Materials and methods for treatment of apolipoprotein c3 (apociii)-related disordersCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 1846US11407997B2Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Granted Aug 9, 2022·0 cites·15 claims
- 1946US2021180091A1Materials and methods for treatment of hemoglobinopathiesVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 2045US2020248168A1Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (pcsk9)-related disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 2144US2020216857A1Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 2244US2020095579A1Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 2343US2020040061A1Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 2441US2019365929A1Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Samarth Kulkarni files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →